for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Medtronic PLC

MDT.N

現在値

89.58USD

変化

-0.91(-1.01%)

出来高

327,517

本日のレンジ

89.50

 - 

90.47

52週レンジ

86.95

 - 

135.84

∙ 約20分前の相場を表示しています。

適時開示

FDA Says Medtronic Conducted Recall Of HVAD System to Inform health care providers, patients Of Battery Performance Issues

June 30 (Reuters) - FDA::FDA - MEDTRONIC CONDUCTED RECALL OF HEARTWARE VENTRICULAR ASSIST DEVICE SYSTEM TO INFORM HEALTH CARE PROVIDERS, PATIENTS OF BATTERY PERFORMANCE ISSUES.FDA - MEDTRONIC PROVIDED INFORMATION ABOUT HVAD SYSTEM'S BATTERY ELECTRICAL FAULTS CAUSED BY INTERACTION BETWEEN BATTERY SOFTWARE AND INTERNAL COMPONENT.

FDA Says Medtronic Recalls Heartware Hvad System Batteries Due To Battery Failure

June 23 (Reuters) - U.S. FDA::FDA SAYS MEDTRONIC RECALLS HEARTWARE HVAD SYSTEM BATTERIES DUE TO BATTERY FAILURE.FDA SAYS MEDTRONIC REPORTS ONE DEATH ASSOCIATED WITH THIS RECALL, AND TWO COMPLAINTS IN AFFECTED LOT.FDA SAYS IDENTIFIED MEDTRONIC'S RECALL OF HEARTWARE HVAD SYSTEM BATTERIES AS A CLASS I RECALL.Further company coverage: MDT.N. ((Reuters.Briefs@thomsonreuters.com;)).

Medtronic Reports Full Year And Fourth Quarter Fiscal Year 2022 Financial Results

May 26 (Reuters) - Medtronic PLC <MDT.N>::MEDTRONIC REPORTS FULL YEAR AND FOURTH QUARTER FISCAL YEAR 2022 FINANCIAL RESULTS; ANNOUNCES 8% DIVIDEND INCREASE.Q4 NON-GAAP EARNINGS PER SHARE $1.52.Q4 GAAP EARNINGS PER SHARE $1.10.SEES FY NON-GAAP EARNINGS PER SHARE $5.53 TO $5.65 INCLUDING ITEMS.COMPANY ISSUES FY23 GUIDANCE.Q4 RESULTS AFFECTED BY TEMPORARY GLOBAL SUPPLY CHAIN IMPACTS AND CHINA LOCKDOWNS.MID-SINGLE DIGIT FY22 REVENUE GROWTH; Q4 RESULTS AFFECTED BY TEMPORARY GLOBAL SUPPLY CHAIN IMPACTS AND CHINA LOCKDOWNS.Q4 REVENUE OF $8.1 BILLION DECREASED 1% REPORTED AND INCREASED 1% ORGANIC.GLOBAL SUPPLY CHAIN AND COVID-19 CONTROLS IN CHINA CREATED ACUTE IMPACTS TO OUR RESULTS IN Q4.NEUROSCIENCE Q4 REVENUE OF $2.299 BILLION WAS FLAT YEAR-OVER-YEAR AS REPORTED AND INCREASED 2% ORGANIC.Q4 CARDIOVASCULAR REVENUE OF $2.961 BILLION INCREASED 2% AS REPORTED AND 5% ORGANIC.CRANIAL & SPINAL TECHNOLOGIES Q4 REVENUE OF $1.165 BILLION DECREASED 2% AS REPORTED AND 1% ORGANIC.EXPECTS ORGANIC REVENUE GROWTH IN ITS FISCAL YEAR 2023 IN RANGE OF 4% TO 5%.SURGICAL INNOVATIONS Q4 REVENUE OF $1.491 BILLION DECREASED 3% AS REPORTED AND WAS FLAT YEAR-OVER-YEAR ORGANIC DUE TO SUPPLY CONSTRAINTS.MEDTRONIC - IF RECENT FOREIGN CURRENCY EXCHANGE RATES HOLD, FISCAL YEAR 2023 REVENUE WOULD BE NEGATIVELY AFFECTED BY ABOUT $1.0 BILLION TO $1.1 BILLION.EXPECTS FISCAL YEAR 2023 NON-GAAP EPS IN RANGE OF $5.53 TO $5.65.REMAINS COMMITTED TO RETURNING A MINIMUM OF 50 PERCENT OF ITS FREE CASH FLOW TO SHAREHOLDERS.

Medtronic And DaVita Announce New Kidney Health Technology Company

May 26 (Reuters) - DaVita Inc <DVA.N>::MEDTRONIC AND DAVITA ANNOUNCE NEW KIDNEY HEALTH TECHNOLOGY COMPANY.MEDTRONIC PLC - COMPANIES JOIN FORCES TO ACCELERATE KIDNEY CARE DEVICE INNOVATION AND IMPROVE PATIENT OUTCOMES.MEDTRONIC PLC - UNDER TERMS, NEWCO WILL BE CO-OWNED BY MEDTRONIC AND DAVITA, EACH WITH EQUAL EQUITY STAKES.MEDTRONIC PLC - UNDER TERMS, NEWCO WILL BE CO-OWNED BY MEDTRONIC AND DAVITA, EACH WITH EQUAL EQUITY STAKES, AND LED BY AN INDEPENDENT MANAGEMENT TEAM.MEDTRONIC PLC - MEDTRONIC WILL CONTRIBUTE ITS RENAL CARE SOLUTIONS (RCS) BUSINESS INCLUDING CURRENT PRODUCT PORTFOLIO.MEDTRONIC PLC - NO OTHER MEDTRONIC PRODUCTS OR PORTFOLIOS, INCLUDING THOSE IN AV ACCESS PORTFOLIO IN PERIPHERAL VASCULAR HEALTH BUSINESS, ARE INCLUDED.MEDTRONIC PLC - BOTH COMPANIES WILL PROVIDE AN INITIAL INVESTMENT TO FUND NEWCO AND FUTURE CERTAIN OPERATING CAPITAL.

Medtronic PLC Says Unit Medtronic Global Holdings S.C.A. Entered Into Term Loan Agreement

May 2 (Reuters) - Medtronic PLC <MDT.N>::MEDTRONIC PLC - ON MAY 2, UNIT MEDTRONIC GLOBAL HOLDINGS S.C.A. ENTERED INTO A TERM LOAN AGREEMENT.MEDTRONIC PLC - LOAN AGREEMENT PROVIDES FOR AN UNSECURED TERM LOAN IN AN AGGREGATE PRINCIPAL AMOUNT OF UP TO JPY300 BILLION , WITH A TERM OF 364 DAYS.MEDTRONIC PLC - ON MAY 2, EXPECTS TO DELIVER NOTICE OF REDEMPTION OF ALL OF OUTSTANDING $1,900 MILLION OF MEDTRONIC, INC.'S 3.500% SENIOR NOTES DUE 2025.MEDTRONIC PLC - ON MAY 2, EXPECTS TO DELIVER A NOTICE OF REDEMPTION OF ALL OF OUTSTANDING $368 MILLION OF MEDTRONIC LUXCO'S 3.350% SENIOR NOTES DUE 2027.MEDTRONIC PLC - REDEMPTION DATE FOR MEDTRONIC LUXCO'S 3.350% SENIOR NOTES DUE 2027 WILL BE MAY 17, 2022.MEDTRONIC PLC - REDEMPTION DATE FOR MEDTRONIC, INC.'S 3.500% SENIOR NOTES DUE 2025 WILL BE JUNE 1, 2022.Further company coverage: MDT.N. ((reuters.briefs@thomsonreuters.com;)).

FDA Says Medtronic Recalls Harmony Delivery Catheter, Part Of Transcatheter Pulmonary Valve (Tpv) System, For Risk Of Capsule Break During Use

April 26 (Reuters) - FDA::FDA - MEDTRONIC RECALLS HARMONY DELIVERY CATHETER, PART OF TRANSCATHETER PULMONARY VALVE (TPV) SYSTEM, FOR RISK OF CAPSULE BREAK DURING USE.FDA - FDA HAS IDENTIFIED HARMONY DELIVERY CATHETER RECALL AS A CLASS I RECALL.FDA - THERE HAVE BEEN 6 REPORTED COMPLAINTS FROM CLINICAL CASES, ONE INJURY, AND NO DEATHS ASSOCIATED WITH USE OF HARMONY DELIVERY CATHETER SYSTEM.FDA - MEDTRONIC RECALLING HARMONY DELIVERY CATHETER DUE TO POSSIBLITY THAT BOND HOLDING CAPSULE AT DELIVERY CATHETER END MAY BREAK DURING PROCEDURE.Further company coverage: MDT.N. ((Reuters.Briefs@thomsonreuters.com;)).

Medtronic Names New Chief Scientific, Medical, And Regulatory Officer

April 25 (Reuters) - Medtronic PLC <MDT.N>::MEDTRONIC NAMES NEW CHIEF SCIENTIFIC, MEDICAL, AND REGULATORY OFFICER.MEDTRONIC PLC - LAURA MAURI, M.D., M.S.C. HAS BEEN APPOINTED MEDTRONIC CHIEF SCIENTIFIC, MEDICAL AND REGULATORY OFFICER.

FDA Says Medtronic Recalls Turbohawk Plus Directional Atherectomy System Due To Risk Of Tip Damage During Use

March 9 (Reuters) - FDA::FDA SAYS MEDTRONIC RECALLS TURBOHAWK PLUS DIRECTIONAL ATHERECTOMY SYSTEM DUE TO RISK OF TIP DAMAGE DURING USE.FDA SAYS MEDTRONIC'S TURBOHAWK PLUS DIRECTIONAL ATHERECTOMY SYSTEM RECALL IS A CLASS I RECALL.

Medtronic Reports Third Quarter Fiscal 2022 Financial Results

Feb 22 (Reuters) - Medtronic PLC <MDT.N>::MEDTRONIC REPORTS THIRD QUARTER FISCAL 2022 FINANCIAL RESULTS.SEES Q4 NON-GAAP EARNINGS PER SHARE $1.56 TO $1.58.Q3 NON-GAAP EARNINGS PER SHARE $1.37.Q3 GAAP EARNINGS PER SHARE $1.10.ISSUES Q4 REVENUE AND EPS GUIDANCE.QTRLY REVENUE OF $7.8 BILLION WAS FLAT YEAR-OVER-YEAR AS REPORTED AND GREW 2% ORGANIC.QTRLY CARDIOVASCULAR REVENUE OF $2.745 BILLION INCREASED 1% AS REPORTED AND 3% ORGANIC.QTRLY CRANIAL & SPINAL TECHNOLOGIES REVENUE OF $1.102 BILLION INCREASED 2% AS REPORTED AND 3% ORGANIC.EXPECTS Q4 ORGANIC REVENUE GROWTH OF APPROXIMATELY 5.5%.QTRLY NEUROSCIENCE REVENUE OF $2.144 BILLION INCREASED 1% AS REPORTED AND 2% ORGANIC.Q3 REVENUE RESULTS REFLECT UNFAVORABLE MARKET IMPACT OF COVID-19 AND HEALTH SYSTEM LABOR SHORTAGES ON MEDICAL DEVICE PROCEDURE VOLUMES.QTRLY MEDICAL SURGICAL REVENUE OF $2.290 BILLION DECREASED 1% AS REPORTED AND INCREASED 1% ORGANIC.Q3 EARNINGS PER SHARE VIEW $1.36, REVENUE VIEW $7.88 BILLION -- REFINITIV IBES DATA.IMPACT OF COVID-19 RESURGENCE ON HEALTHCARE PROCEDURE VOLUMES, PARTICULARLY IN U.S., PEAKED IN FINAL WEEKS OF OUR QUARTER IN JANUARY.EXPECT HEALTHCARE PROCEDURES TO REACCELERATE POST-OMICRON.Q4 EARNINGS PER SHARE VIEW $1.57, REVENUE VIEW $8.49 BILLION -- REFINITIV IBES DATA.

Medtronic Announces Results Showing Meaningful Pain Relief Using DTM Spinal Cord Stimulation Endurance Therapy

Jan 14 (Reuters) - Medtronic PLC <MDT.N>::MEDTRONIC ANNOUNCES RESULTS SHOWING MEANINGFUL PAIN RELIEF USING DTM™ SPINAL CORD STIMULATION ENDURANCE THERAPY.MEDTRONIC PLC - DTM SCS ENDURANCE THERAPY ENABLES LONG-LASTING RECHARGE-FREE PERFORMANCE ON VANTA AND 5-MINUTE RECHARGE ON INTELLIS NEUROSTIMULATORS.MEDTRONIC - 3-MONTH DATA SHOWS THERAPY ENABLES BETWEEN 5.5-7.5 YEARS DEVICE LONGEVITY WHEN PROGRAMMED ON VANTA RECHARGE-FREE NEUROSTIMULATOR.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up